HGH Fragment 176-191

HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal (carboxy-terminal) region of the human growth hormone (hGH) molecule, spanning roughly amino acids 176 to 191. This short segment was identified as the part of growth hormone responsible for its lipolytic, or fat-mobilizing, activity, distinct from the regions that drive skeletal growth and insulin-like actions. The best-studied representative of this lipolytic domain is AOD9604, a stabilized analog carrying an added N-terminal tyrosine, developed by researchers at Monash University and later advanced as a candidate anti-obesity drug ^[1][2][3].

The defining scientific interest in the fragment is that it appears to reproduce growth hormone's effect on fat metabolism while avoiding its other consequences. In obese (ob/ob) and Zucker rodent models, chronic treatment with the fragment reduced body weight gain, increased in vivo fat oxidation, and raised plasma glycerol, an index of lipolysis, yet, unlike intact hGH, it did not cause hyperglycemia or suppress insulin secretion ^[1][3]. Notably, the fragment does not compete for the growth hormone receptor and does not stimulate cell proliferation the way full-length hGH does, supporting the idea that growth hormone can behave as a pro-hormone whose fragments carry separable activities ^[1].

Because of this profile, the fragment attracted attention as a potential obesity therapeutic and reached clinical development under the AOD9604 designation, appearing in reviews of anti-obesity drug pipelines ^[4][5]. It has also been explored beyond fat loss, including intra-articular use in an animal osteoarthritis model where it was associated with enhanced cartilage regeneration ^[6]. AOD9604 is recognized in sports anti-doping frameworks and is monitored by mass-spectrometry-based testing methods, reflecting its status as a performance-adjacent peptide ^[7]. It is not an approved medicine and is handled as a research peptide.

HGH Fragment 176-191 is a synthetic fragment of growth hormone marketed for fat loss; robust human safety data are lacking, and most claims (including that it spares GH's effects on blood sugar) come from limited or preclinical work. Reported effects are generally mild, such as injection-site reactions, but long-term safety and the purity of research-grade material are uncharacterized. It should be regarded as an unapproved research peptide.

HGH Fragment 176-191 corresponds to the last sixteen amino acids at the C-terminal end of human growth hormone, the region long associated with the hormone's fat-metabolizing activity. The stabilized synthetic analogue known as AOD9604 was characterized by Frank Ng and colleagues at Monash University in Australia, who reported its metabolic actions in obese Zucker rats in 2000 ^[1]. The compound was subsequently developed by the Australian company Metabolic Pharmaceuticals as an orally administered anti-obesity candidate and advanced into human clinical trials during the 2000s. Although it did not reproduce its striking animal weight-loss results in those later human trials, AOD9604 was granted generally-recognized-as-safe (GRAS) status in the United States and remains a focused research tool for the lipolytic actions of growth hormone.

The fragment is regarded as one of the more elegant attempts to isolate a single useful action of growth hormone; the fat-burning C-terminal signal, while leaving behind the growth-promoting and blood-sugar effects of the intact hormone. Researchers value the clean mechanistic story, since measurements show it stimulates lipolysis and fat oxidation without binding the growth hormone receptor or impairing insulin sensitivity. In peptide and body-composition circles it is discussed favorably as a targeted approach to fat loss. Honesty requires noting the main limitation: the most impressive results come from obese-animal models, and human trials did not confirm meaningful weight loss compared with placebo, so its appeal rests more on its clever biology than on proven clinical efficacy.